NASHUA, N.H. – February 16, 2021 – iCAD,
. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced
that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will
participate in a fireside chat during the BTIG Virtual MedTech, Digital Health,
Life Science & Diagnostic Tools Conference on Thursday, February 18th
at 4:30pm ET and will also conduct one-on-one meetings with investors.

The presentation will be webcast live and accessible online via the
investors section of the Company’s website, 


About iCAD, Inc.


in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.


ProFound AI™ is a high-performing
workflow solution for 2D and 3D mammography, or digital breast tomosynthesis
(DBT), featuring the latest in deep-learning artificial intelligence. In 2018,
ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial
intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and
Health Canada licensed that same year. It offers clinically proven time-savings
benefits to radiologists, including a reduction of reading time by 52.7
percent, thereby halving the amount of time it takes radiologists to read 3D
mammography datasets. Additionally, ProFound AI for DBT improved radiologist
sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2


The Xoft System
is FDA-cleared, CE marked and licensed in a growing number of countries for the
treatment of cancer anywhere in the body. It uses a proprietary miniaturized
x-ray source to deliver a precise, concentrated dose of radiation directly to
the tumor site, while minimizing risk of damage to healthy tissue in nearby
areas of the body.


For more information, visit and


Forward-Looking Statements


Certain statements contained in this News
Release constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements about
the future prospects for the Company’s technology platforms and products. Such
forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the ability of
alleviate the burden to our health system and minimize a
patient’s potential exposure to Covid-19, to be more beneficial for patients
that traditional therapy or to be accepted by patients or clinicians,
  the impact of supply and manufacturing
constraints or difficulties, uncertainty of future sales levels,
to defend itself
in litigation matters, protection of patents and other
proprietary rights, the impact of supply and manufacturing constraints or
difficulties, product market acceptance, possible technological obsolescence of
products, increased competition, litigation and/or government regulation,
changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a
decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,”
“continue,” “anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at and on the
SEC’s website at



Media inquiries:

Jessica Burns, iCAD  



Investor Relations:

Jeremy Feffer, LifeSci Advisors